The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti, Federica Morano, Roberto Moretto, Salvatore Corallo, Federica Marmorino, Sara Lonardi, Lorenza Rimassa, Andrea Sartore-Bianchi, Beatrice Borelli, Marco Tampellini, Sara Bustreo, Matteo Claravezza, Alessandra Boccaccino, Roberto Murialdo, Alberto Zaniboni, Gianluca Tomasello, Fotios Loupakis, Vincenzo AdamoGiuseppe Tonini, Enrico Cortesi, Filippo de Braud, Chiara Cremolini, Filippo Pietrantonio

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the prognostic power of a new comprehensive biomarker, the Pan-Immune-Inflammation Value (PIV), in patients with mCRC receiving first-line therapy.METHODS: In the present pooled-analysis, we included patients enrolled in the Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. A cut-off was determined using the maximally selected rank statistics method. Generalised boosted regression (GBR), the Kaplan-Meier method and Cox hazards regression models were used for survival analyses.RESULTS: A total of 438 patients were included. Overall, 208 patients (47%) had a low-baseline PIV and 230 (53%) had a high-baseline PIV. Patients with high PIV experienced a worse PFS (HR, 1.66; 95% CI, 1.36-2.03, P 
Original languageEnglish
Pages (from-to)403-409
Number of pages7
JournalBr. J. Cancer
Volume123
Issue number3
DOIs
Publication statusPublished - Aug 2020

Fingerprint Dive into the research topics of 'The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials'. Together they form a unique fingerprint.

Cite this